Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$68.27
-10.8%
$56.20
$22.28
$85.60
$27.09B0.949.47 million shs9.16 million shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$123.90
+0.1%
$111.72
$71.13
$123.91
$9.79B1.142.18 million shs2.06 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$298.70
-1.4%
$289.89
$249.00
$385.22
$32.77B0.49270,452 shs254,502 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$35.97
-2.3%
$31.08
$10.90
$37.00
$25.87B1.115.99 million shs6.24 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-14.41%+37.53%+33.97%+108.20%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
0.00%+0.14%+0.36%+20.60%+52.02%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.00%+0.35%+14.77%-3.54%+16.82%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.00%+2.39%+20.99%+27.51%+220.59%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$68.27
-10.8%
$56.20
$22.28
$85.60
$27.09B0.949.47 million shs9.16 million shs
Nuvalent, Inc. stock logo
NUVL
Nuvalent
$123.90
+0.1%
$111.72
$71.13
$123.91
$9.79B1.142.18 million shs2.06 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$298.70
-1.4%
$289.89
$249.00
$385.22
$32.77B0.49270,452 shs254,502 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$35.97
-2.3%
$31.08
$10.90
$37.00
$25.87B1.115.99 million shs6.24 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
0.00%-14.41%+37.53%+33.97%+108.20%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
0.00%+0.14%+0.36%+20.60%+52.02%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.00%+0.35%+14.77%-3.54%+16.82%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
0.00%+2.39%+20.99%+27.51%+220.59%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
1.83
Reduce$38.27-43.95% Downside
Nuvalent, Inc. stock logo
NUVL
Nuvalent
2.15
Hold$127.733.09% Upside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.80
Moderate Buy$391.3831.03% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.75
Moderate Buy$33.59-6.61% Downside

Current Analyst Ratings Breakdown

Latest NUVL, ONC, MRNA, and ROIV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetEqual Weight$33.00 ➝ $39.00
7/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetOutperform$436.00 ➝ $451.00
7/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetSector Perform$38.00 ➝ $45.00
7/7/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetUnderperform$34.00 ➝ $38.00
7/7/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Boost Price TargetBuy$413.00 ➝ $416.00
7/3/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
DowngradeStrong-BuyHold
7/1/2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
Reiterated RatingMarket Outperform$396.00
6/26/2026
Moderna, Inc. stock logo
MRNA
Moderna
Boost Price TargetOverweight$69.00 ➝ $77.00
6/24/2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
DowngradeOutperformMarket Perform$172.00 ➝ $124.00
6/18/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingHold
6/12/2026
Moderna, Inc. stock logo
MRNA
Moderna
Reiterated RatingSell (D-)
(Data available from 7/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$1.94B13.93N/AN/A$22.14 per share3.08
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/A$15.95 per shareN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.34B6.13$3.91 per share76.42$39.77 per share7.51
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$8.26M3,132.22N/AN/A$7.35 per share4.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$2.82B-$8.15N/AN/AN/A-143.55%-26.64%-19.32%7/31/2026 (Estimated)
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$4.4766.8228.18N/A8.94%12.06%6.69%N/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$299.77M-$0.60N/AN/AN/A-3,629.19%-20.54%-19.43%8/10/2026 (Estimated)

Latest NUVL, ONC, MRNA, and ROIV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.44N/AN/AN/A$0.25 millionN/A
7/31/2026Q2 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$2.0316N/AN/AN/A$101.65 millionN/A
5/20/2026Q4 2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.2893$0.28+$0.5693$0.28$3.41 million$2.52 million
5/7/2026Q1 2026
Nuvalent, Inc. stock logo
NUVL
Nuvalent
-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A
5/1/2026Q1 2026
Moderna, Inc. stock logo
MRNA
Moderna
-$3.02-$3.40-$0.38-$3.40$236.37 million$389.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
0.08
2.41
2.35
Nuvalent, Inc. stock logo
NUVL
Nuvalent
N/A
16.14
16.14
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.20
3.64
3.27
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
18.37
18.37

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
97.26%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
64.76%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
10.80%
Nuvalent, Inc. stock logo
NUVL
Nuvalent
5.02%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
6.19%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
10.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
4,700396.79 million353.93 millionOptionable
Nuvalent, Inc. stock logo
NUVL
Nuvalent
4079.00 million75.03 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.72 million102.93 millionN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860719.27 million641.59 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Moderna stock logo

Moderna NASDAQ:MRNA

$68.27 -8.29 (-10.83%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$68.32 +0.06 (+0.08%)
As of 07/10/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Nuvalent stock logo

Nuvalent NASDAQ:NUVL

$123.90 +0.07 (+0.06%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$123.95 +0.05 (+0.04%)
As of 07/10/2026 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$298.70 -4.13 (-1.36%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$298.48 -0.22 (-0.07%)
As of 07/10/2026 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$35.97 -0.84 (-2.28%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$35.78 -0.20 (-0.54%)
As of 07/10/2026 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.